130 related articles for article (PubMed ID: 21563652)
1. Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
Borbath I; Stärkel P
Acta Gastroenterol Belg; 2011 Mar; 74(1):34-44. PubMed ID: 21563652
[TBL] [Abstract][Full Text] [Related]
2. The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.
Schneider-Merck T; Borbath I; Charette N; De Saeger C; Abarca J; Leclercq I; Horsmans Y; Stärkel P
Eur J Cancer; 2009 Jul; 45(11):2050-60. PubMed ID: 19427195
[TBL] [Abstract][Full Text] [Related]
3. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y
Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255
[TBL] [Abstract][Full Text] [Related]
4. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats.
Borbath I; Leclercq IA; Sempoux C; Abarca-Quinones J; Desaeger C; Horsmans Y
Chem Biol Interact; 2010 Jan; 183(1):238-48. PubMed ID: 19874807
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide.
Borbath I; Leclercq IA; Abarca-Quinones J; Desaeger C; Lebrun V; Moulin P; Sempoux C; Horsmans Y
Cancer Sci; 2007 Dec; 98(12):1831-9. PubMed ID: 17900309
[TBL] [Abstract][Full Text] [Related]
7. Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.
Wu L; Pang Y; Qin G; Xi G; Wu S; Wang X; Chen T
PLoS One; 2017; 12(2):e0171840. PubMed ID: 28182780
[TBL] [Abstract][Full Text] [Related]
8. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.
Borbath I; Leclercq I; Moulin P; Sempoux C; Horsmans Y
Eur J Cancer; 2007 Jul; 43(11):1755-63. PubMed ID: 17582756
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
Khwaja A; Sharpe CC; Noor M; Kloog Y; Hendry BM
Kidney Int; 2005 Aug; 68(2):474-86. PubMed ID: 16014024
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis.
Li S; Ghoshal S; Sojoodi M; Arora G; Masia R; Erstad DJ; Lanuti M; Hoshida Y; Baumert TF; Tanabe KK; Fuchs BC
J Gastrointest Surg; 2019 Jan; 23(1):101-111. PubMed ID: 30367397
[TBL] [Abstract][Full Text] [Related]
11. Administration of Steamed and Freeze-Dried Mature Silkworm Larval Powder Prevents Hepatic Fibrosis and Hepatocellular Carcinogenesis by Blocking TGF-β/STAT3 Signaling Cascades in Rats.
Lee DY; Yun SM; Song MY; Ji SD; Son JG; Kim EH
Cells; 2020 Feb; 9(3):. PubMed ID: 32121064
[TBL] [Abstract][Full Text] [Related]
12. Enhancing FTS (Salirasib) efficiency via combinatorial treatment.
Wolfson E; Schmukler E; Schokoroy ST; Kloog Y; Pinkas-Kramarski R
Biol Cell; 2015 May; 107(5):130-43. PubMed ID: 25735913
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.
Yu J; Shen B; Chu ES; Teoh N; Cheung KF; Wu CW; Wang S; Lam CN; Feng H; Zhao J; Cheng AS; To KF; Chan HL; Sung JJ
Hepatology; 2010 Jun; 51(6):2008-19. PubMed ID: 20512989
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.
Schiffer E; Housset C; Cacheux W; Wendum D; Desbois-Mouthon C; Rey C; Clergue F; Poupon R; Barbu V; Rosmorduc O
Hepatology; 2005 Feb; 41(2):307-14. PubMed ID: 15660382
[TBL] [Abstract][Full Text] [Related]
15. Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.
Wu B; Yuan Y; Liu J; Shang H; Dong J; Liang X; Wang D; Chen Y; Wang C; Zhou Y; Jing H; Cheng W
J Nanobiotechnology; 2021 Jun; 19(1):177. PubMed ID: 34118951
[TBL] [Abstract][Full Text] [Related]
16. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.
DePeralta DK; Wei L; Ghoshal S; Schmidt B; Lauwers GY; Lanuti M; Chung RT; Tanabe KK; Fuchs BC
Cancer; 2016 Apr; 122(8):1216-27. PubMed ID: 26914713
[TBL] [Abstract][Full Text] [Related]
17. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y
Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334
[TBL] [Abstract][Full Text] [Related]
18. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid.
Reif S; Aeed H; Shilo Y; Reich R; Kloog Y; Kweon YO; Bruck R
J Hepatol; 2004 Aug; 41(2):235-41. PubMed ID: 15288472
[TBL] [Abstract][Full Text] [Related]
19. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
Nasr M; Selima E; Hamed O; Kazem A
Eur J Pharmacol; 2014 Jan; 723():267-75. PubMed ID: 24291100
[TBL] [Abstract][Full Text] [Related]
20. [Induction of necrosis in the hepatocellular carcinoma HepG2 xenografts treated with SOM230].
Xie Y; Chen S; Wang CH; Tang CW
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):759-64. PubMed ID: 19874692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
